IRIS
AMADORI, SERGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 82.855
EU - Europa 6.931
AS - Asia 1.775
SA - Sud America 52
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 16
AF - Africa 11
Totale 91.661
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 82.806
DE - Germania 2.639
UA - Ucraina 1.215
CN - Cina 1.159
IE - Irlanda 719
IT - Italia 598
GB - Regno Unito 493
KR - Corea 369
RU - Federazione Russa 311
FI - Finlandia 254
SE - Svezia 254
FR - Francia 230
PL - Polonia 81
JP - Giappone 41
CA - Canada 36
NL - Olanda 35
IN - India 33
UZ - Uzbekistan 30
BE - Belgio 27
BR - Brasile 24
AT - Austria 17
CL - Cile 15
VN - Vietnam 15
PH - Filippine 14
TR - Turchia 14
AU - Australia 13
EU - Europa 13
IR - Iran 13
CH - Svizzera 12
ES - Italia 12
HK - Hong Kong 11
SG - Singapore 11
MX - Messico 9
ID - Indonesia 8
PE - Perù 8
TW - Taiwan 8
EG - Egitto 7
GR - Grecia 7
PK - Pakistan 7
PT - Portogallo 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AR - Argentina 5
DK - Danimarca 5
IL - Israele 5
IQ - Iraq 5
MY - Malesia 5
NO - Norvegia 5
SA - Arabia Saudita 5
DM - Dominica 4
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
A1 - Anonimo 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
LK - Sri Lanka 2
NZ - Nuova Zelanda 2
QA - Qatar 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
FJ - Figi 1
KW - Kuwait 1
KZ - Kazakistan 1
LT - Lituania 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
NG - Nigeria 1
PS - Palestinian Territory 1
RS - Serbia 1
SD - Sudan 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
Totale 91.661
Salva come PNG Salva come JPEG
Città #
Woodbridge 27.051
Wilmington 22.140
Houston 18.980
Fairfield 2.518
Ann Arbor 2.131
Chandler 1.371
Ashburn 1.224
Jacksonville 1.123
Seattle 1.064
Cambridge 848
Dearborn 766
Dublin 699
Medford 550
Beijing 450
New York 305
Zhengzhou 298
Lawrence 258
Rome 183
Mülheim 158
San Diego 120
Menlo Park 87
Kraków 68
Milan 65
Falls Church 64
Shanghai 61
Creede 55
Hefei 55
Boardman 53
Redwood City 51
Nanjing 49
Norwalk 49
University Park 48
London 45
Mountain View 43
San Mateo 37
Kunming 35
Guangzhou 33
Palo Alto 32
Nürnberg 31
Verona 30
Saint Petersburg 25
Bologna 24
Hangzhou 24
Brussels 23
Los Angeles 18
Nanchang 17
Toronto 17
Kilburn 16
Phoenix 15
Shenyang 15
Helsinki 14
Santa Clara 14
Auburn Hills 13
Jinan 13
Seongnam 13
Seoul 13
Center 12
Groningen 12
Hebei 12
Detroit 11
Dong Ket 11
San Francisco 11
Chicago 9
Hounslow 9
Indiana 9
Redmond 9
Florence 8
Fuzhou 8
Lima 8
Pune 8
Turin 8
Chiswick 7
Innsbruck 7
São Paulo 7
Brescia 6
Chengdu 6
Manila 6
Mumbai 6
Quzhou 6
Tokyo 6
Washington 6
Wuhan 6
Acton 5
Chaoyang 5
Diyarbakır 5
Leawood 5
Louisville 5
Madrid 5
Montreal 5
Vienna 5
Wenzhou 5
Chennai 4
Costa Mesa 4
Felgueiras 4
Kuala Lumpur 4
Naples 4
New Bedfont 4
Ningbo 4
Philadelphia 4
Rieti 4
Totale 83.797
Salva come PNG Salva come JPEG
Nome #
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 599
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 539
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 474
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 471
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas 471
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy 462
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 456
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation 450
A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype 448
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 447
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 441
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 439
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 437
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 437
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 436
6-phosphogluconate dehydrogenase deficiency in an Italian family 435
Acute foetal distress and umbilical cord blood banking 435
Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia 434
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 434
Treatment of multiple myeloma: A randomized study of three different regimens 427
A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0) 427
Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian multicenter study 426
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia final results of AML-13, a randomized phase-3 study 426
Clinical significance of CD38 expression in chronic lymphocytic leukemia 425
Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia - Analysis of prognostic factors 425
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice 423
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 422
Treatment of elderly patients (>= 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols 421
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up 420
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 420
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 420
Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura 419
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 419
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 419
Use of arsenic trioxide in haematological malignancies: Insight into the clinical development of a novel agent 417
Placental/Umbilical cord blood: experience of St. Eugenio Hospital collection center 417
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 415
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 413
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 412
Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separators 412
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 411
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 411
Biological features of acute myeloid leukemia in the elderly 411
null 410
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 410
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial of the EORTC and GIMEMA consortium (AML-17) 410
Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes 409
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 409
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 409
Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab 408
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 407
Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience 406
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia 406
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 406
High expression levels of vla-4 (CD49d) on mobilised peripheral blood stem cells are associated with rapid engraftment in multiple myeloma patients receiving autologous transplant 405
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 405
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 405
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 404
Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC 403
Randomized Phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes 403
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura 401
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia 401
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant. 401
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 401
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 400
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 399
Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera 399
Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825 398
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 398
Sequential administration of gemtuzubab ozogamicin (GO) and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: Interim results of the EORTC leukemia group AML-15A phase II trial 397
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients 397
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 397
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 397
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study 396
All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia 396
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 396
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 396
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults 395
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab 394
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial 393
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 393
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review 392
AML-M0: a biological and clinical profile 392
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients. 391
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 391
A new system for quality control in hematopoietic progenitor cell units before reinfusion in autologous transplant. 391
Cardiovascular involvement in thalassaemic patients with pseudoxanthoma elasticum-like skin lesions: A long-term follow-up study 389
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 389
Induction of Apoptosis by Pyrrolobenzothiadiazepines (PBTDs) in cell lines and in 12 chronic myeloid leukaemia patients and imatinib-resistant 387
Gemtuzumab ozogamicin (Mylotarg((R))) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups 387
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 387
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). 386
Unrelated Cord Blood transplantaion for children with high risk myelodysplastic syndrome 386
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 386
Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation 384
Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease 382
FISH analysis for CML monitoring? 381
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 380
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 380
Molecular characterization of paediatric idiopathic hypereosinophilia 379
Totale 41.403
Salva come PNG Salva come JPEG
Categoria #
all - tutte 152.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 152.406
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20195.207 0 0 0 0 0 0 0 0 0 0 2.821 2.386
2019/202024.191 2.137 2.021 1.725 2.277 2.174 2.695 2.236 2.100 1.971 1.872 1.368 1.615
2020/202113.333 1.556 1.603 1.377 1.782 1.351 1.386 1.672 1.232 354 288 555 177
2021/20222.559 91 290 104 124 72 251 135 132 142 262 150 806
2022/20233.622 404 252 210 410 282 762 338 212 400 31 244 77
2023/2024995 141 41 62 29 146 408 87 45 15 20 1 0
Totale 92.121